SWDAF yields 0.14% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 4
Combined, SWDAF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SWDAF + JNJ for your $10,000?
Software Aktiengesellschaft provides software development, licensing, maintenance, and IT services in Germany, the United States, and internationally. It operates through three segments: Digital Business Platform, Adabas & Natural, and Professional Services. The company offers Internet of Things (IoT) and analytics solutions comprising Cumulocity IoT for integrating digital equipment and sensors through an IoT device management and application enablement platform, as well as provides streaming analytics for big data analytics in real time and solutions for predictive analytics, artificial intelligence (AI), and machine learning; and TrendMiner, an intuitive Web-based analytics platform for visualization of industrial processes and process data. It also provides webMethods that integrate systems, applications, and processes through application programming interfaces or direct connections and orchestrate them in the form of microservices; ARIS for modeling, documenting, and optimizing business processes; Alfabet, which enables enterprise architecture mapping and optimal decision making for IT investments; Adabas & Natural for transaction processing; and CONNX for data integration, virtualization, and replication. In addition, the company offers professional services, which include implementation, development, and upgrade/migration services. Further, it has strategic alliance with Persistent System to develop industry solutions and accelerators for healthcare and life sciences; banking, financial services, and insurance; and telecommunications. Software Aktiengesellschaft was founded in 1969 and is headquartered in Darmstadt, Germany.
Full SWDAF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.